NanoPhoria
Milan
About NanoPhoria
NanoPhoria is a biotechnology company focused on the development of innovative cardiovascular treatments. It specializes in a non-viral, nano-in-micro delivery system for biologics, designed to target the heart directly. This preclinical-stage company is exploring the potential of inhalable therapies, utilizing tissue-directed delivery methods for therapeutic peptides and RNAs. NanoPhoria's approach aims to revolutionize the treatment of cardiovascular diseases by offering a versatile, non-viral drug delivery platform, formulated for both inhalation and other administration routes. With a dedicated team, NanoPhoria is committed to advancing cardiovascular health through groundbreaking research and development.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $116.1M
- Funding stage: Early Stage Venture
- Last round: Series A (Oct 2025)
- Website: nanophoria.com
- Phone: [email protected]
Industries & Categories
Analytics, Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/nanophoria-105070 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.